Literature DB >> 17431814

Do Finnish women using hormone replacement therapy need more information about risks.

Miia J Tiihonen1, Anna-Mari Heikkinen, Riitta S Ahonen.   

Abstract

OBJECTIVE: In 1998, the Women's Health Initiative (WHI) in 2002 and the Million Women Study (MWS) in 2003 have shown a need for re-evaluation of the benefits and adverse reactions of hormone replacement therapy (HRT). Consequently the authorities in Europe and USA have issued new recommendations against the use of HRT. The aim of this study was to examine women's perceptions of HRT since the publication of the Women's Health Initiative study and the Million Women Study, and the kind of sources women use to obtain information about HRT.
METHOD: The data was collected with questionnaire survey in the autumn 2003 among 315 women using HRT.
RESULTS: One third of the respondents (35%) had experienced fears concerning HRT use, and more than half (52%) reported that the debate in the media had markedly influenced them; they have experienced fears or worries, considered discontinuation or discussed with the physician. Whereas the most common source of information concerning the benefits of HRT was the physician (74%), the most common source of information concerning the risks of HRT was the media (78%).
CONCLUSION: This study shows that women using HRT should get more information about the risks from health care professionals. Physicians and pharmacists have an opportunity to alleviate fears and to help women to critically evaluate the information they get from the media. Such discussions are also important to women who have been using HRT for years.

Entities:  

Mesh:

Year:  2007        PMID: 17431814     DOI: 10.1007/s11096-007-9115-1

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  16 in total

1.  Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns.

Authors:  S Sihvo; R Ahonen; H Mikander; E Hemminki
Journal:  Fam Pract       Date:  2000-04       Impact factor: 2.267

2.  Effect of therapeutic class on counseling in community pharmacies.

Authors:  Kirsti K Vainio; Marja S A Airaksinen; Tarja T Hyykky; K Hannes Enlund
Journal:  Ann Pharmacother       Date:  2002-05       Impact factor: 3.154

3.  Postmenopausal hormone replacement therapy for the primary prevention of chronic condition. Recommendations and rationale. U.S. Preventive Services Task Force.

Authors: 
Journal:  Am Fam Physician       Date:  2003-01-15       Impact factor: 3.292

4.  Effect of clinical trial publicity on HRT prescribing in Ireland.

Authors:  C Usher; M Teeling; K Bennett; J Feely
Journal:  Eur J Clin Pharmacol       Date:  2006-01-24       Impact factor: 2.953

5.  Self-medication of dyspepsia: how appropriate is it?

Authors:  S Sihvo; E Hemminki
Journal:  Scand J Gastroenterol       Date:  1997-09       Impact factor: 2.423

6.  Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757].

Authors:  Piret Veerus; Sirpa-Liisa Hovi; Krista Fischer; Mati Rahu; Matti Hakama; Elina Hemminki
Journal:  Maturitas       Date:  2006-02-28       Impact factor: 4.342

7.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

8.  Women's views of optimal risk communication and decision making in general practice consultations about the menopause and hormone replacement therapy.

Authors:  Fiona M Walter; Jon D Emery; Margaret Rogers; Nicky Britten
Journal:  Patient Educ Couns       Date:  2004-05

9.  Current opinions and understandings of menopausal women about hormone replacement therapy (HRT)-the University of Florida experience.

Authors:  Eric Levens; R Stan Williams
Journal:  Am J Obstet Gynecol       Date:  2004-08       Impact factor: 8.661

10.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

View more
  4 in total

1.  Hormonal contraceptive users' self-reported benefits, adverse reactions, and fears in 2001 and 2007.

Authors:  Miia Tiihonen; Hanna-Mari Leppänen; Anna-Mari Heikkinen; Riitta Ahonen
Journal:  Patient       Date:  2008-07-01       Impact factor: 3.883

2.  Information sources used by women in Finland who use hormonal contraceptives.

Authors:  Miia Tiihonen; Anna-Mari Heikkinen; Hanna-Mari Leppänen; Riitta Ahonen
Journal:  Pharm World Sci       Date:  2009-10-30

3.  Trends in the receipt of medicines information among Finnish adults in 1999-2014: a nationwide repeated cross-sectional survey.

Authors:  Niina Mononen; Marja S A Airaksinen; Katri Hämeen-Anttila; Satu Helakorpi; Marika Pohjanoksa-Mäntylä
Journal:  BMJ Open       Date:  2019-06-14       Impact factor: 2.692

4.  Pharmacy Customers' Experiences With Electronic Prescriptions: Cross-Sectional Survey on Nationwide Implementation in Finland.

Authors:  Elina Lämsä; Johanna Timonen; Riitta Ahonen
Journal:  J Med Internet Res       Date:  2018-02-23       Impact factor: 5.428

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.